This inventor holds 4 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Daiichi Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Microcide Pharmaceuticals, Inc.. Active years: 2002-2009.
Company Filing History:
2 out of 200 
1 out of 461 
1 out of 26 Years Active: 2002-2009
Title: Innovations by Inventor Toshiharu Ohta
Introduction
Toshiharu Ohta, based in Tokyo, Japan, is a prominent inventor with a portfolio that includes four patents. His contributions in the field of medicine, particularly concerning cardiovascular health, highlight his innovation and dedication to improving human health.
Latest Patents
Ohta’s latest patents revolve around diamine derivatives, characterized by specific chemical structures designed to prevent and treat various serious health conditions. One such compound is represented by the formula (1): Q-Q-T-N(R)-Q-N(R)-T-Q where R denotes hydrogen atoms or similar groups; Q signifies a cyclic hydrocarbon group; and T represents carbonyl groups. These compounds serve as agents against cerebral infarction, myocardial infarction, angina pectoris, pulmonary embolism, and several other serious medical conditions. His innovative work in developing these compounds showcases his commitment to addressing critical health challenges.
Career Highlights
Throughout his career, Toshiharu Ohta has worked with reputable companies, including Daiichi Pharmaceutical Co., Ltd., and Microcide Pharmaceuticals, Inc. His experience in these organizations has significantly contributed to his proficiency and expertise in pharmaceutical innovations.
Collaborations
Ohta has collaborated with notable colleagues such as Satoshi Komoriya and Toshiharu Yoshino. These partnerships have fostered an environment of shared knowledge and creativity, leading to advancements in pharmaceutical development.
Conclusion
Toshiharu Ohta's innovative contributions to the field of medicine through his patents demonstrate his substantial impact on health-related technologies. His ongoing work is likely to influence future research and development, paving the way for new therapeutic solutions.